Differentiated Th1 autoreactive effector cells can induce experimental autoimmune encephalomyelitis in the absence of IL-12 and CD40/CD40L interactions

被引:9
|
作者
Mendel, I [1 ]
Shevach, EM [1 ]
机构
[1] NIH, NIAID, Immunol Lab, Bethesda, MD 20892 USA
关键词
EAE/MS; autoimmunity; Th1/Th2; cytokines; in vivo animal models;
D O I
10.1016/S0165-5728(01)00465-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IL-12 plays a critical role in the priming of Th1 responses to bacterial/parasitic antigens and autoantigens. Several studies have demonstrated a dependency on CD40/CD40L interactions and IL-12 for maintenance of both antibacterial/parasitic and autoreactive Th1 cells in vivo. However, it is still unclear if fully differentiated Th1 effectors require continued stimulation by IL-12. We demonstrate that the proliferative response and IFN-gamma production by a fully differentiated T cell line specific for myelin oligodendrocyte glycoprotein are completely independent of IL-12 and CD40/CD40L interactions. The capacity of this line to adoptively transfer experimental autoimmune encephalomyelitis is also independent of IL-12 and CD40/CD40L. These results have important implications regarding the therapeutic usefulness of blockade of IL-12 or the CD40/CD40L pathway for treatment of autoimmune disease. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:65 / 73
页数:9
相关论文
共 50 条
  • [41] Induction of Th1 autoimmune effector cells is dependent on IL-12 mediated upregulation of IL-12 receptor β2 chain expression
    Chang, JT
    Shevach, EM
    Segal, BM
    FASEB JOURNAL, 1998, 12 (04): : A307 - A307
  • [42] Suppressive effect of the CD40L blockade in T-cell mediated autoimmunity is reversed by IL-12
    Constantinescu, CS
    Hilliard, B
    Wysocka, M
    Ventura, ES
    Bhopale, MK
    Trinchieri, G
    Rostami, A
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S51 - S51
  • [43] IL-12 production by rheumatoid synovial cells is differently regulated by the signal via CD40 and TNFα
    Kitagawa, M
    Mitsui, H
    Onobori, M
    Suzuki, H
    Sumida, T
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S38 - S38
  • [44] Effector memory CD4+ T cells induce damaging innate inflammation and autoimmune pathology by engaging CD40 and TNFR on myeloid cells
    McDaniel, Margaret M.
    Chawla, Amanpreet Singh
    Jain, Aakanksha
    Meibers, Hannah E.
    Saha, Irene
    Gao, Yajing
    Jain, Viral
    Roskin, Krishna
    Way, Sing Sing
    Pasare, Chandrashekhar
    SCIENCE IMMUNOLOGY, 2022, 7 (67) : eabk0182
  • [45] Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
    Pandey, Madhu S.
    Wang, Chunlei
    Umlauf, Scott
    Lin, Shihua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [46] CD40 on B cells and on dendritic cells mediates experimental autoimmune encephalomyelitis pathogenesis through distinct and complementary mechanisms
    Lu, Ying
    Xu, Max
    Zhang, Ray
    Wagner, David H.
    Hodes, Richard
    JOURNAL OF IMMUNOLOGY, 2021, 206
  • [47] Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4+ T cells
    Eck, SC
    Turka, LA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1999, 48 (06) : 336 - 341
  • [48] Engineering Tumor Cells with Tumor Necrosis Factor α (TNF-α) or CD40 Ligand (CD40L) Genes Induce Anti-tumor Immune Responses
    Daneshmandi, Saeed
    Shahrokhi, Somayeh
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2019, 25 (02) : 427 - 436
  • [49] Engineering Tumor Cells with Tumor Necrosis Factor α (TNF-α) or CD40 Ligand (CD40L) Genes Induce Anti-tumor Immune Responses
    Saeed Daneshmandi
    Somayeh Shahrokhi
    International Journal of Peptide Research and Therapeutics, 2019, 25 : 427 - 436
  • [50] Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4+ T cells
    Steven C. Eck
    Laurence A. Turka
    Cancer Immunology, Immunotherapy, 1999, 48 : 336 - 341